A systematic review of 18 qualitative studies identified eight major categories of factors influencing why cancer patients discontinue treatment, ranging from financial barriers and side effects to family dynamics and spiritual beliefs. Understanding these drivers could help clinicians provide better-tailored support and communication.
Treatment withdrawal is rarely a simple choice. Researchers conducted a systematic review and meta-synthesis of 18 qualitative studies published between 2000 and 2024, synthesizing data from patient interviews and focus groups to understand why cancer patients stop treatment. The analysis organized factors into two broad categories: endogenous (internal to the patient) and exogenous (external environment).
The researchers identified eight distinct sub-categories driving withdrawal decisions. Financial and insurance challenges emerged as a major barrier, with patients reporting inability to afford treatment, travel costs, or medications despite having insurance. Healthcare team communication ranked second: patients cited insufficient information about treatment options, poor doctor-patient relationships, and feeling unheard by clinicians. This suggests that the clinical relationship itself significantly influences whether patients continue care.
Cultural and social factors formed another key category. Patients' ethnic backgrounds, cultural health beliefs, and community norms shaped their treatment decisions. Spiritual and religious beliefs also played a substantial role, with some patients prioritizing faith-based healing or viewing treatment continuation as spiritually misaligned. Family functioning was equally important: family support (or lack thereof), family disagreements about treatment, and caregiving burden all influenced decisions. Personal attributes like age, education level, and individual values about quality of life versus quantity of life affected continuation rates.
Emotional factors and medication side effects completed the picture. Patients reported anxiety, depression, hopelessness, and fear driving withdrawal, while side effects like nausea, fatigue, pain, and cognitive impairment made continuing treatment psychologically and physically unsustainable. Notably, these factors rarely operated in isolation. A patient might face financial hardship, experience severe side effects, struggle with family disagreement, and harbor spiritual doubts simultaneously. The review emphasizes that withdrawal decisions emerge from this complex interplay rather than from single causes.
If you're facing cancer treatment decisions: This research validates that your concerns are multifaceted and legitimate. Financial strain, side effects, family dynamics, cultural values, and spiritual beliefs are all recognized by evidence as real factors in treatment decisions. Effective conversations with your clinical team should address all of these, not just medical efficacy. Request time to discuss what matters most to you and explore whether modifications to treatment (dosing, delivery method, supportive care) might address your specific barriers.
If you're supporting someone in cancer treatment: Understanding that withdrawal often reflects financial, emotional, or relational stress rather than loss of hope can shift how you approach support. Ask what specific barriers they face. Financial assistance programs, transportation services, mental health support, and family counseling are often available but underutilized. Open communication about fears and values, rather than pressure to continue, tends to strengthen both adherence and relationships.
For healthcare providers: The systematic review underscores that clinical conversations need structural attention to non-medical factors. Brief screening for financial hardship, explicit assessment of side effect burden, inquiry into family dynamics, and respect for cultural and spiritual values should be routine, not afterthoughts. Patients who feel genuinely heard and supported across these domains are more likely to continue treatment when it aligns with their values, or to make informed decisions about alternatives when it doesn't.
| Attribute | Value |
|---|---|
| Study type | Systematic review and meta-synthesis (qualitative) |
| Studies included | 18 qualitative studies |
| Search period | 2000-2024 |
| Databases searched | PubMed, Web of Science, Scopus, CINAHL |
| Initial hits | 348 studies |
| Analysis method | Conventional content analysis with Sandelowski and Barroso meta-synthesis framework |
| Primary codes extracted | 177 |
| Main themes identified | 1 main theme, 2 categories, 8 sub-categories |
| Evidence tier | A (systematic review of qualitative data) |
| Journal | Cancer Medicine |
| PubMed ID | 42760607 |
Ghahramani, F., Dehghan, M., & Azari, S. (2024). Why do cancer patients decide to withdraw their treatment? A systematic review and meta-synthesis. *Cancer Medicine*. PMID: 42760607
ProtocolEngine provides general health information based on published research. This is not medical advice. Consult a healthcare professional before starting any supplement or health protocol.